Header Logo

Connection

John Harris to Female

This is a "connection" page, showing publications John Harris has written about Female.
Connection Strength

0.493
  1. Frisoli ML, Ko WC, Martinez N, Afshari K, Wang Y, Garber M, Harris JE. Single-Cell RNA Sequencing Reveals Molecular Signatures that Distinguish Allergic from Irritant Contact Dermatitis. J Invest Dermatol. 2025 May; 145(5):1117-1126.e14.
    View in: PubMed
    Score: 0.047
  2. Refat MA, Strassner JP, Frisoli ML, Rashighi M, Richmond J, Nada E, Saleh R, El-Hamd MA, Goldberg D, Mahmoud BH, Harris JE. Lesional CD8+ T-Cell Number Predicts Surgical Outcomes of Melanocyte-Keratinocyte Transplantation Surgery for Vitiligo. J Invest Dermatol. 2023 11; 143(11):2275-2282.e6.
    View in: PubMed
    Score: 0.043
  3. Paquette GM, Sherman S, Akabane A, Harris JE. Adolescent extra-truncal progressive macular hypomelanosis. Pediatr Dermatol. 2023 Jul-Aug; 40(4):702-705.
    View in: PubMed
    Score: 0.042
  4. Fukuda K, Okamura K, Riding RL, Fan X, Afshari K, Haddadi NS, McCauley SM, Guney MH, Luban J, Funakoshi T, Yaguchi T, Kawakami Y, Khvorova A, Fitzgerald KA, Harris JE. AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma. J Exp Med. 2021 09 06; 218(9).
    View in: PubMed
    Score: 0.038
  5. Riding RL, Richmond JM, Fukuda K, Harris JE. Type I interferon signaling limits viral vector priming of CD8+ T cells during initiation of vitiligo and melanoma immunotherapy. Pigment Cell Melanoma Res. 2021 07; 34(4):683-695.
    View in: PubMed
    Score: 0.036
  6. Rosmarin D, Pandya AG, Lebwohl M, Grimes P, Hamzavi I, Gottlieb AB, Butler K, Kuo F, Sun K, Ji T, Howell MD, Harris JE. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020 07 11; 396(10244):110-120.
    View in: PubMed
    Score: 0.035
  7. Tkachenko E, Refat MA, Balzano T, Maloney ME, Harris JE. Patient satisfaction and physician productivity in shared medical appointments for vitiligo. J Am Acad Dermatol. 2019 Nov; 81(5):1150-1156.
    View in: PubMed
    Score: 0.032
  8. Strassner JP, Rashighi M, Ahmed Refat M, Richmond JM, Harris JE. Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity. J Am Acad Dermatol. 2017 May; 76(5):847-855.e5.
    View in: PubMed
    Score: 0.028
  9. Harris JE. IFN-? in Vitiligo, Is It the Fuel or the Fire? Acta Derm Venereol. 2015 Jul; 95(6):643-4.
    View in: PubMed
    Score: 0.025
  10. Patel A, Sener A, Lee SY. Reversed diastolic flow in a renal transplant due to ureteric obstruction from intraluminal blood clot. J Clin Ultrasound. 2022 May; 50(4):521-524.
    View in: PubMed
    Score: 0.019
  11. Harris JE, Sutton DA, Rubin A, Wickes B, De Hoog GS, Kovarik C. Exophiala spinifera as a cause of cutaneous phaeohyphomycosis: case study and review of the literature. Med Mycol. 2009 Feb; 47(1):87-93.
    View in: PubMed
    Score: 0.016
  12. Eleftheriadou V, Desai S, Bae JM, Taylor S, Meurant JM, Abdallah M, Ju HJ, Benzekri L, Wolkerstorfer A, B?hm M, Xiang LF, Rush E, Hamzavi IH, Passeron T, Lim H, Harris JE, Parsad D, Huggins R, Schneider A, Kolios A, Rosmarin D, Mohammad TF, Esmat SM, Jones J, Retzer A, Seneschal J, Gkini MA, Ahmed A, Thompson A, Pandya AG, Cruz Rivera S, Kpenou FC, Ezzedine K. Definition of Severity and Relapse for Vitiligo: An International Consensus Statement. JAMA Dermatol. 2026 May 01; 162(5):515-524.
    View in: PubMed
    Score: 0.013
  13. Wang Y, Afshari K, Haddadi NS, Lopes CS, Eng CL, Whiteman LM, Martinez N, Kyawe PP, Anufrieva KS, Wei K, Frieda K, Rosenbach M, Vleugels RA, Gallucci S, Harris JE, Rashighi M, Garber M. A spatially coordinated keratinocyte-fibroblast circuit recruits MMP9+ myeloid cells to drive type I interferon-driven inflammation in photosensitive autoimmunity. Nat Immunol. 2026 Jun; 27(6):1184-1196.
    View in: PubMed
    Score: 0.013
  14. Sherman S, Duskin-Bitan H, Agiv T, Bar D, Marom-Haham L, Levi A, Mimouni D, Chen LC, Harris JE, Levitt JB, Schonmann Y, Cohen AD, Netzer D. Bidirectional association between vitiligo and melasma: A large-scale population-based study. Indian J Dermatol Venereol Leprol. 2026 Mar-Apr; 92(2):150-156.
    View in: PubMed
    Score: 0.013
  15. Fakih HH, Zain Ui Abideen M, Rachid MO, Gross KY, Ormsby TJR, Ross VM, Gagnon R, Dahlke C, Furgal RC, Lochmann C, Summers A, Sleiman HF, F?rst SM, Jackson SN, Gordilho JO, Bouix-Peter C, Portal T, Tang Q, Harris JE, Khvorova A, Blanchard C, Alterman JF. Intradermal delivery of lipophilic siRNAs enables prolonged skin retention and sustained gene silencing in a porcine model. Nat Commun. 2026 Feb 03; 17(1).
    View in: PubMed
    Score: 0.013
  16. Ezzedine K, Parsad D, Harris JE, van Geel N, Gardner J, Bibeau K, Gao J, Ren H, Hamzavi IH. Depression and depressive symptoms among people living with vitiligo: findings from the cross-sectional, population-based global VALIANT survey. J Dermatolog Treat. 2025 Dec; 36(1):2504082.
    View in: PubMed
    Score: 0.012
  17. Tissera KA, Buros-Stein A, Delva C, Mayur O, Hawryluk EB, Harris JE, Garza-Mayers AC. Investigation of Hearing Loss in Pediatric Vitiligo. Pediatr Dermatol. 2025 Sep-Oct; 42(5):1016-1019.
    View in: PubMed
    Score: 0.012
  18. Bibeau K, Ezzedine K, Harris JE, van Geel N, Grimes P, Parsad D, Tulpule M, Gardner J, Valle Y, Tlhong Matewa G, LaFiura C, Lindley A, Ren H, Hamzavi IH. Mental Health and Psychosocial Quality-of-Life Burden Among Patients With Vitiligo: Findings From the Global VALIANT Study. JAMA Dermatol. 2023 10 01; 159(10):1124-1128.
    View in: PubMed
    Score: 0.011
  19. Damsky W, Patel D, Garelli CJ, Garg M, Wang A, Dresser K, Deng A, Harris JE, Richmond J, King B. Jak Inhibition Prevents Bleomycin-Induced Fibrosis in Mice and Is Effective in Patients with Morphea. J Invest Dermatol. 2020 07; 140(7):1446-1449.e4.
    View in: PubMed
    Score: 0.008
  20. Mande P, Zirak B, Ko WC, Taravati K, Bride KL, Brodeur TY, Deng A, Dresser K, Jiang Z, Ettinger R, Fitzgerald KA, Rosenblum MD, Harris JE, Marshak-Rothstein A. Fas ligand promotes an inducible TLR-dependent model of cutaneous lupus-like inflammation. J Clin Invest. 2018 07 02; 128(7):2966-2978.
    View in: PubMed
    Score: 0.008
  21. Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017 Oct; 77(4):675-682.e1.
    View in: PubMed
    Score: 0.007
  22. Chong SZ, Evrard M, Devi S, Chen J, Lim JY, See P, Zhang Y, Adrover JM, Lee B, Tan L, Li JL, Liong KH, Phua C, Balachander A, Boey A, Liebl D, Tan SM, Chan JK, Balabanian K, Harris JE, Bianchini M, Weber C, Duchene J, Lum J, Poidinger M, Chen Q, R?nia L, Wang CI, Larbi A, Randolph GJ, Weninger W, Looney MR, Krummel MF, Biswas SK, Ginhoux F, Hidalgo A, Bachelerie F, Ng LG. CXCR4 identifies transitional bone marrow premonocytes that replenish the mature monocyte pool for peripheral responses. J Exp Med. 2016 10 17; 213(11):2293-2314.
    View in: PubMed
    Score: 0.007
  23. Li JL, Lim CH, Tay FW, Goh CC, Devi S, Malleret B, Lee B, Bakocevic N, Chong SZ, Evrard M, Tanizaki H, Lim HY, Russell B, Renia L, Zolezzi F, Poidinger M, Angeli V, St John AL, Harris JE, Tey HL, Tan SM, Kabashima K, Weninger W, Larbi A, Ng LG. Neutrophils Self-Regulate Immune Complex-Mediated Cutaneous Inflammation through CXCL2. J Invest Dermatol. 2016 Feb; 136(2):416-424.
    View in: PubMed
    Score: 0.006
  24. Wu S, Li WQ, Cho E, Harris JE, Speizer F, Qureshi AA. Use of permanent hair dyes and risk of vitiligo in women. Pigment Cell Melanoma Res. 2015 Nov; 28(6):744-6.
    View in: PubMed
    Score: 0.006
  25. Ram?n HE, Cejas PJ, LaRosa D, Rahman A, Harris JE, Zhang J, Hunter C, Choi Y, Turka LA. EGR-2 is not required for in vivo CD4 T cell mediated immune responses. PLoS One. 2010 Sep 23; 5(9):e12904.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.